Solicited administration-site A, and systemic B, adverse events with onset within 7 d after FLU-aQIV and RSVPreF3 OA co-administration or sequential administration (exposed set). Confidence intervals are depicted as error bars. Fever was defined as a temperature ≥38.0 °C. Grade 3 adverse events were defined as administration-site erythema or swelling with a diameter >100 mm, fever with a temperature >39.0 °C, administration-site pain, arthralgia, fatigue, headache, and myalgia that prevented normal activity. Co-Ad, group of participants who received RSVPreF3 OA and FLU-aQIV concomitantly on day 1 (visit 1); Control, group of participants who received FLU-aQIV on day 1 (visit 1) and RSVPreF3 OA on day 31 (visit 2). Abbreviations: FLU-aQIV, adjuvanted inactivated seasonal quadrivalent influenza vaccine; MGI, mean geometric increase; RSVPreF3 OA, respiratory syncytial virus (RSV) prefusion F protein-based vaccine.